Auto-Immunity Highlights最新文献

{"title":"Clinical comparisons between previously diagnosed SLE and newly diagnosed SLE by kidney biopsy.","authors":"Pantipa Tonsawan,&nbsp;Kittisak Sawanyawisuth","doi":"10.1186/s13317-020-00140-2","DOIUrl":"https://doi.org/10.1186/s13317-020-00140-2","url":null,"abstract":"<p><strong>Background: </strong>Lupus nephritis is a type of major organ involvement in systemic lupus erythematosus (SLE) patients that leads to higher rates of morbidity and mortality and may present initially in 28% of SLE patients. However, there are limited data available on clinical differences or predictors for biopsy-proven lupus nephritis in established versus newly diagnosed SLE cases.</p><p><strong>Methods: </strong>Adult patients undergoing kidney biopsy for the first time with a diagnosis of lupus nephritis were eligible for inclusion. Patients were categorized into two groups: those with previously diagnosed SLE and those with newly diagnosed SLE by kidney biopsy. Factors associated with newly diagnosed SLE were determined using logistic regression analysis.</p><p><strong>Results: </strong>There were 68 patients diagnosed with lupus nephritis by kidney biopsy. Of those, 31 cases (45.58%) were newly diagnosed. The newly diagnosed SLE group was significantly older (36.87 vs 30.95 years) and had a lower proportion of females (74.19% vs 91.89%) than the previously diagnosed group. A new-onset hypertension was the only factor independently associated with newly diagnosed SLE by kidney biopsy. The adjusted odds ratio (95% CI) was 5.152 (1.046, 25.363).</p><p><strong>Conclusions: </strong>Nearly half of the biopsy-proven lupus nephritis cases in this study were patients with newly diagnosed SLE. Patients with previously diagnosed SLE and newly diagnosed SLE by kidney biopsy had clinical differences.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2020-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00140-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38661582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey.","authors":"Lieve Van Hoovels,&nbsp;Sylvia Broeders,&nbsp;Edward K L Chan,&nbsp;Luis Andrade,&nbsp;Wilson de Melo Cruvinel,&nbsp;Jan Damoiseaux,&nbsp;Markku Viander,&nbsp;Manfred Herold,&nbsp;Wim Coucke,&nbsp;Ingmar Heijnen,&nbsp;Dimitrios Bogdanos,&nbsp;Jaime Calvo-Alén,&nbsp;Catharina Eriksson,&nbsp;Ana Kozmar,&nbsp;Liisa Kuhi,&nbsp;Carolien Bonroy,&nbsp;Bernard Lauwerys,&nbsp;Sofie Schouwers,&nbsp;Laurence Lutteri,&nbsp;Martine Vercammen,&nbsp;Miroslav Mayer,&nbsp;Dina Patel,&nbsp;William Egner,&nbsp;Kari Puolakka,&nbsp;Andrea Tesija-Kuna,&nbsp;Yehuda Shoenfeld,&nbsp;Maria José Rego de Sousa,&nbsp;Marcos Lopez Hoyos,&nbsp;Antonella Radice,&nbsp;Xavier Bossuyt","doi":"10.1186/s13317-020-00139-9","DOIUrl":"https://doi.org/10.1186/s13317-020-00139-9","url":null,"abstract":"<p><strong>Background: </strong>The International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) has recently proposed nomenclature in order to harmonize ANA indirect immunofluorescence (IIF) pattern reporting. ICAP distinguishes competent-level from expert-level patterns. A survey was organized to evaluate reporting, familiarity, and considered clinical value of ANA IIF patterns.</p><p><strong>Methods: </strong>Two surveys were distributed by European Autoimmunity Standardization Initiative (EASI) working groups, the International Consensus on ANA Patterns (ICAP) and UK NEQAS to laboratory professionals and clinicians.</p><p><strong>Results: </strong>438 laboratory professionals and 248 clinicians from 67 countries responded. Except for dense fine speckled (DFS), the nuclear competent patterns were reported by > 85% of the laboratories. Except for rods and rings, the cytoplasmic competent patterns were reported by > 72% of laboratories. Cytoplasmic IIF staining was considered ANA positive by 55% of clinicians and 62% of laboratory professionals, with geographical and expertise-related differences. Quantification of fluorescence intensity was considered clinically relevant for nuclear patterns, but less so for cytoplasmic and mitotic patterns. Combining IIF with specific extractable nuclear antigens (ENA)/dsDNA antibody testing was considered most informative. Of the nuclear competent patterns, the centromere and homogeneous pattern obtained the highest scores for clinical relevance and the DFS pattern the lowest. Of the cytoplasmic patterns, the reticular/mitochondria-like pattern obtained the highest scores for clinical relevance and the polar/Golgi-like and rods and rings patterns the lowest.</p><p><strong>Conclusion: </strong>This survey confirms that the major nuclear and cytoplasmic ANA IIF patterns are considered clinically important. There is no unanimity on classifying DFS, rods and rings and polar/Golgi-like as a competent pattern and on reporting cytoplasmic patterns as ANA IIF positive.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00139-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38633900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Castleman disease and SLE in a G6PD-deficient Marfan patient: a case report and literature review.","authors":"Sami Alhoulaiby,&nbsp;Lina Okar,&nbsp;Haya Samaan,&nbsp;Hisham Qalaani","doi":"10.1186/s13317-020-00138-w","DOIUrl":"https://doi.org/10.1186/s13317-020-00138-w","url":null,"abstract":"<p><strong>Introduction: </strong>Marfan syndrome, G6PD deficiency, systemic lupus erythematosus (SLE), and Castleman disease are four distinctive, thoroughly investigated entities whose coincidence was never reported. However, occurrence in pairs was sporadically mentioned in literature.</p><p><strong>Case presentation: </strong>We report a 15-year-old Caucasian G6PD deficient Marfan male patient, who presented with tonic-clonic seizures, fever, a hemolytic episode, and general symptoms. After the discovery of hepatosplenomegaly, malar rash, and painless lymphadenopathy, further testing diagnosed a multifocal Castleman disease of the hyaline vascular subtype and systemic lupus erythematosus with lupus nephritis that got 35 points on the 2019 EULAR/ACR criteria. G6PD deficiency, SLE & Castleman disease, and seizures were handled medically with eventual improvement in the patient's condition.</p><p><strong>Discussion and conclusion: </strong>It is extremely rare to discover the gathering of these four diseases in the same patient. Marfan syndrome and G6PD deficiency were proven by respective clinical and laboratory examinations. Castleman disease that tends to occur in older age groups was confirmed via pathological study of a lymph node biopsy, which was compatible with the HHV-8 negative type reported in Asian countries. SLE is part of the differential diagnosis for Castleman disease, yet the newest evidence strongly supports its presence as a distinct entity. However, no concrete proof is available to suggest a causative relationship between the four of them, rather than a coincidental occurrence.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2020-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00138-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38563390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case-control and population case-control design.","authors":"Rossella Murtas,&nbsp;Anita Andreano,&nbsp;Federico Gervasi,&nbsp;Davide Guido,&nbsp;David Consolazio,&nbsp;Sara Tunesi,&nbsp;Laura Andreoni,&nbsp;Maria Teresa Greco,&nbsp;Maria Elena Gattoni,&nbsp;Monica Sandrini,&nbsp;Antonio Riussi,&nbsp;Antonio Giampiero Russo","doi":"10.1186/s13317-020-00141-1","DOIUrl":"https://doi.org/10.1186/s13317-020-00141-1","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 epidemic has paralleled with the so called infodemic, where countless pieces of information have been disseminated on putative risk factors for COVID-19. Among those, emerged the notion that people suffering from autoimmune diseases (AIDs) have a higher risk of SARS-CoV-2 infection.</p><p><strong>Methods: </strong>The cohort included all COVID-19 cases residents in the Agency for Health Protection (AHP) of Milan that, from the beginning of the outbreak, developed a web-based platform that traced positive and negative cases as well as related contacts. AIDs subjects were defined ad having one the following autoimmune disease: rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren disease, ankylosing spondylitis, myasthenia gravis, Hashimoto's disease, acquired autoimmune hemolytic anemia, and psoriatic arthritis. To investigate whether AID subjects are at increased risk of SARS-CoV-2 infection, and whether they have worse prognosis than AIDs-free subjects once infected, we performed a combined analysis of a test-negative design case-control study, a case-control with test-positive as cases, and one with test-negative as cases (CC-NEG).</p><p><strong>Results: </strong>During the outbreak, the Milan AHP endured, up to April 27th 2020, 20,364 test-positive and 34,697 test-negative subjects. We found no association between AIDs and being positive to COVID-19, but a statistically significant association between AIDs and being negative to COVID-19 in the CC-NEG. If, as likely, test-negative subjects underwent testing because of respiratory infection symptoms, these results imply that autoimmune diseases may be a risk factor for respiratory infections in general (including COVID-19), but they are not a specific risk factor for COVID-19. Furthermore, when infected by SARS-CoV-2, AIDs subjects did not have a worse prognosis compared to non-AIDs subjects. Results highlighted a potential unbalance in the testing campaign, which may be correlated to the characteristics of the tested person, leading specific frail population to be particularly tested.</p><p><strong>Conclusions: </strong>Lack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":"11 1","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2020-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00141-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9675895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human placental extract attenuates neurological symptoms in the experimental autoimmune encephalomyelitis model of multiple sclerosis-a putative approach in MS disease?","authors":"Mir Hadi Jazayeri,&nbsp;Khadijeh Barzaman,&nbsp;Reza Nedaeinia,&nbsp;Tayebe Aghaie,&nbsp;Morteza Motallebnezhad","doi":"10.1186/s13317-020-00137-x","DOIUrl":"https://doi.org/10.1186/s13317-020-00137-x","url":null,"abstract":"<p><strong>Background: </strong>Different studies have demonstrated the anti-inflammatory effects of human placental extract both in vivo and in vitro. Considering the chronic inflammatory nature of multiple sclerosis (MS) disease, we examined whether or not the administration of human placental extract is able to attenuate the neurological symptoms detected in experimental autoimmune encephalomyelitis (EAE) model of MS.</p><p><strong>Methods: </strong>The injected myelin oligodendrocyte glycoprotein (MOG) induced EAE in mice, and treatment began from day 4 post-injection by intraperitoneal administration of 0.2 mg/kg human placental extract, repeated every other day up to day 31 post-injection. At the end of the treatment, luxol fast blue (LBS) staining and hematoxylin and eosin (H&E) staining were performed to evaluate the demyelination of neurons and inflammatory responses, respectively. Further assessed were the serum concentrations of IL-23 and IL-27.</p><p><strong>Results: </strong>The administration of human placental extract was able to significantly reduce the mean clinical score in EAE mice, decrease the pro-inflammatory process and attenuate neural demyelination. Moreover, while the serum concentration of IL-23 was significantly diminished in the EAE mice receiving human placental extract compared to the non-treated EAE group, IL-27 concentration was significantly increased.</p><p><strong>Conclusions: </strong>Our findings demonstrated the administration of human placental extract could significantly attenuate the neurological symptoms in the EAE model of MS in part through modulating the serum levels of IL-23 and IL-27 and enhancing neuroprotection and myelin repair.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2020-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00137-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38454663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoantibodies directed against α1-adrenergic receptor and endothelin receptor A in patients with prostate cancer.","authors":"Gerd Wallukat,&nbsp;Burkhard Jandrig,&nbsp;Niels-Peter Becker,&nbsp;Johann J Wendler,&nbsp;Peter Göttel,&nbsp;Johannes Müller,&nbsp;Martin Schostak,&nbsp;Ingolf Schimke","doi":"10.1186/s13317-020-00136-y","DOIUrl":"https://doi.org/10.1186/s13317-020-00136-y","url":null,"abstract":"<p><strong>Background: </strong>For prostate cancer, signaling pathways induced by over-boarding stimulation of G-protein coupled receptors (GPCR) such as the endothelin, α1- and β-adrenergic, muscarinic and angiotensin 1 receptors were accused to support the carcinogenesis. However, excessive receptor stimulation by physiological receptor ligands is minimized by a control system that induces receptor sensitization and down-regulation. This system is missing when so-called \"functional autoantibodies\" bind to the GPCR (GPCR-AAB). If GPCR-AAB were found in patients with prostate cancer, uncontrolled GPCR stimulation could make these autoantibodies an additional supporter in prostate cancer.</p><p><strong>Methods: </strong>Using the bioassay of spontaneously beating cultured rat neonatal cardiomyocytes, GPCR-AAB were identified, quantified and characterized in the serum of 25 patients (aged 56-78 years, median 70 years) with prostate cancer compared to 10 male patients (aged 48-82 years, median 64) with urinary stone disorders (controls).</p><p><strong>Results: </strong>Of the cancer patients, 24 (96%) and 17 (68%), respectively, carried autoantibodies directed against the α1-adrenergic receptor (α1-AAB) and endothelin receptor A (ETA-AAB). No patient was negative for both GPCR-AAB. In contrast, ETA-AAB and α1-AAB were absent in all (100%) and 9 (90%) of the 10 control patients, respectively. While α1-AAB targeted a specific epitope of the first extracellular loop of the α1-adrenergic receptor subtype A, an epitope of the second extracellular loop of the ETA receptor was identified as a target of ETA-AAB. As demonstrated in vitro, the functional activity of both autoantibodies found in prostate cancer can be neutralized by the aptamer BC007.</p><p><strong>Conclusions: </strong>We hypothesized that α1-AAB and ETA-AAB, which are highly present in prostate cancer patients, could by their functional activity support carcinogenesis by excessive receptor stimulation. The in vitro demonstrated neutralization of α1- and ETA-AAB by the aptamer BC007 could open the door to complement the treatments already available for prostate cancer.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2020-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00136-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38517560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality and best practice in medical laboratories: specific requests for autoimmunity testing.","authors":"Ulrich Sack, Xavier Bossuyt, Hristina Andreeva, Péter Antal-Szalmás, Nicola Bizzaro, Dimitrios Bogdanos, Elena Borzova, Karsten Conrad, Marie-Agnes Dragon-Durey, Catharina Eriksson, Katarzyna Fischer, Anna-Maija Haapala, Ingmar Heijnen, Manfred Herold, Werner Klotz, Ana Kozmar, Andrea Tesija Kuna, Marcos López Hoyos, Vladimir A Malkov, Lucile Musset, Eszter Nagy, Johan Rönnelid, Yehuda Shoenfeld, Tatjana Sundic, Alexandra Tsirogianni, Raivo Uibo, Maria José Rego Sousa, Jan Damoiseaux","doi":"10.1186/s13317-020-00134-0","DOIUrl":"10.1186/s13317-020-00134-0","url":null,"abstract":"<p><p>Special conditions associated with laboratory autoimmune testing are not well compatible with recent developments in regulatory frameworks such as EN/ISO 15189 accreditation or in vitro diagnostic medical device regulation (IVD-R). In addition, international recommendations, guidelines and disease criteria are poorly defined with respect to requirements on autoantibody testing. Laboratory specialists from Austria, Belgium, Croatia, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Norway, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, and The Netherlands collected information, reported national experience, and identified quality issues in relation to autoantibody testing that require consensus on interpretation of the regulatory frameworks and guidelines. This process has been organized by the European Autoimmunity Standardisation Initiative (EASI). By identifying the critical items and looking for a consensus, our objective was to define a framework for, in particular, EN/ISO accreditation purposes. Here, we present a review of current publications and guidelines in this field to unify national guidelines and deliver in this way a European handout on quality control and accreditation for laboratories involved in autoantibody testing. We focus on quality items that can be checked during accreditation visits. Despite various local varieties, we encountered an overwhelming dedication to quality assurance in all contributing countries.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2020-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38343980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical and the laboratory autoimmunologist: Where do we stand?","authors":"Renato Tozzoli, Nicola Bizzaro","doi":"10.1186/s13317-020-00133-1","DOIUrl":"10.1186/s13317-020-00133-1","url":null,"abstract":"","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2020-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38158255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent angioedema, Guillain-Barré, and myelitis in a girl with systemic lupus erythematosus and CD59 deficiency syndrome.","authors":"Vadood Javadi Parvaneh,&nbsp;Leila Ghasemi,&nbsp;Khosro Rahmani,&nbsp;Reza Shiari,&nbsp;Mahbobeh Mesdaghi,&nbsp;Zahra Chavoshzadeh,&nbsp;Seyed Hassan Tonekaboni","doi":"10.1186/s13317-020-00132-2","DOIUrl":"https://doi.org/10.1186/s13317-020-00132-2","url":null,"abstract":"<p><strong>Background: </strong>CD59 deficiency is a congenital mutation disorder in complement pathway which can present with various manifestations.</p><p><strong>Case presentation: </strong>Herein, we presented an adolescent 16-years-old girl with recurrent attacks of Guillain-Barre in early childhood and then recurrent attacks of angioedema, paresthesia, and myelitis. Finally, she presented with quadriplegia, malar rash, proteinuria, lymphopenia, and high titer of antinuclear antibody. So, the patient developed systemic lupus erythematosus. Furthermore, we performed whole exome sequencing which revealed homozygote mutations in CD59 for the patient and heterozygote one for her parents. CD flow cytometry showed less than 1 percent expression of CD59 on the surface of the patient's peripheral blood cells confirming the disorder. So, she had CD59 deficiency. The patient's episodes were managed with plasma exchanges, corticosteroids, Cyclophosphamide, and Mycophenolate Mofetil which induced and maintained remission.</p><p><strong>Conclusion: </strong>CD59 deficiency can be presented with various clinical features such as neurologic, hematologic, dermatologic, and rheumatologic problems including systemic lupus erythematosus.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2020-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00132-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38108992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome.","authors":"Ilan Volkov,&nbsp;Luciana Seguro,&nbsp;Elaine P Leon,&nbsp;László Kovács,&nbsp;Dirk Roggenbuck,&nbsp;Peter Schierack,&nbsp;Boris Gilburd,&nbsp;Andrea Doria,&nbsp;Maria G Tektonidou,&nbsp;Nancy Agmon-Levin","doi":"10.1186/s13317-020-00131-3","DOIUrl":"https://doi.org/10.1186/s13317-020-00131-3","url":null,"abstract":"<p><strong>Background: </strong>Specific anti-phospholipids antibodies (aPLs) are used as classification criteria of the antiphospholipid syndrome (APS). These aPLs, although essential for diagnosis, do not predict disease phenotypes, which may require specific therapies. Non-criteria aPLs are rarely evaluated and their role is yet to be defined. In the current study, we aimed to examine the association between criteria and non-criteria aPLs and APS phenotypes.</p><p><strong>Methods: </strong>Serum samples from 188 subjects, 130 APS patients and 58 controls were analyzed for the presence of 20 aPLs (IgG and IgM isotypes to cardiolipin (CL), beta2-glycoprotein1 (β2GP1), phosphatidic acid (P-acid), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), annexin-5 (AN) and prothrombin (PT) using a line immunoassay (GA Generic Assays, Germany). Sero-positivity to the different aPLs/aPLs profiles was correlated to APS phenotypes (i.e. arterial thrombosis, CNS manifestations, venous thrombosis, relapsing disease, obstetric morbidity).</p><p><strong>Results: </strong>In this cohort, arterial thrombosis was associated with accumulative number of ≥ 7/20 aPLs evaluated (OR 4.1; CI 95% 1.9-96, p = 0.001) as well as the sole presence of aPT (IgG) (OR 2.3;CI 95% 1.1-5.1, p = 0.03). CNS manifestations were linked with a profile of 4 aPLs (IgG): aPT, aPG, aPI and aAN (OR 2.6;CI 95% 1.1-6.3, p = 0.03). Symptom-free period of ≥ 3 years was linked with lower number of aPLs and the presence of aPI (IgG) (OR 3.0;CI 95% 1.08-8.1, p < 0.05) or aAN (IgG) (OR 3.4;CI 95% 1.08-10.9, p < 0.05). APS related pregnancy morbidity correlated with a profile of 2 aPLs (IgG): aCL and aPS (OR 2.9; CI 95% 1.3-6.5, p < 0.05) or the sole presence of aAN (IgG) (OR 2.8; CI 95% 1.02-8, p = 0.05).</p><p><strong>Conclusion: </strong>In this study, we observed an association between specific criteria/non-criteria aPLs or aPLs profiles and clinical phenotypes of APS. Our data suggest that examination of a wider variety of aPLs may allow better characterization of APS.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":" ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13317-020-00131-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37984555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}